Jason Grebely
#154,660
Most Influential Person Now
Researcher
Jason Grebely's AcademicInfluence.com Rankings
Jason Grebelymedical Degrees
Medical
#3017
World Rank
#3468
Historical Rank
Gastroenterology
#68
World Rank
#70
Historical Rank
Public Health
#478
World Rank
#494
Historical Rank
Download Badge
Medical
Why Is Jason Grebely Influential?
(Suggest an Edit or Addition)Jason Grebely's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. (2017) (1601)
- Epidemiology and natural history of HCV infection (2013) (921)
- Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review (2017) (878)
- Global statistics on alcohol, tobacco and illicit drug use: 2017 status report (2018) (580)
- Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals (2013) (473)
- Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. (2017) (388)
- Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States (2015) (385)
- The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection (2014) (348)
- Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. (2016) (325)
- Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. (2013) (312)
- Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review (2017) (293)
- Global patterns of opioid use and dependence: harms to populations, interventions, and future action (2019) (275)
- Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. (2012) (217)
- Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. (2008) (211)
- Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. (2018) (207)
- Recommendations for the management of hepatitis C virus infection among people who inject drugs. (2015) (206)
- Potential role for Interleukin‐28B genotype in treatment decision‐making in recent hepatitis C virus infection (2010) (195)
- Low uptake of treatment for hepatitis C virus infection in a large community‐based study of inner city residents (2009) (184)
- Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. (2013) (175)
- Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation (2016) (167)
- Hepatitis C virus reinfection in injection drug users (2006) (161)
- Global, regional, and country‐level estimates of hepatitis C infection among people who have recently injected drugs (2018) (159)
- What is killing people with hepatitis C virus infection? (2011) (153)
- Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. (2010) (148)
- Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review. (2017) (147)
- Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease (2015) (144)
- Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. (2018) (140)
- Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. (2021) (134)
- Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. (2018) (130)
- Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011 (2014) (130)
- Direct-acting antiviral agents for HCV infection affecting people who inject drugs (2017) (130)
- Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support (2010) (123)
- The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. (2014) (121)
- Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. (2007) (121)
- Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. (2017) (120)
- Elimination of HCV as a public health concern among people who inject drugs by 2030 – What will it take to get there? (2017) (111)
- Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. (2013) (110)
- Can hepatitis C virus infection be eradicated in people who inject drugs? (2014) (110)
- The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. (2019) (110)
- Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C. (2011) (109)
- Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. (2007) (108)
- Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. (2013) (105)
- Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. (2022) (103)
- Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis (2017) (103)
- MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C (2016) (101)
- Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection (2012) (101)
- Continued low uptake of treatment for hepatitis C virus infection in a large community‐based cohort of inner city residents (2014) (100)
- Reinfection with hepatitis C virus following sustained virological response in injection drug users (2010) (90)
- Mixed HCV infection and reinfection in people who inject drugs—impact on therapy (2015) (90)
- Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. (2016) (89)
- The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC) (2016) (89)
- Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. (2015) (88)
- Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia. (2017) (88)
- Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study. (2015) (88)
- Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. (2016) (88)
- Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users (2007) (83)
- IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis (2017) (83)
- Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay (2018) (81)
- Hepatitis C Virus Phylogenetic Clustering Is Associated with the Social-Injecting Network in a Cohort of People Who Inject Drugs (2012) (81)
- Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. (2019) (79)
- Management of HCV and HIV infections among people who inject drugs. (2011) (78)
- Hepatitis C treatment as prevention: evidence, feasibility, and challenges. (2016) (78)
- Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. (2011) (76)
- Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework (2018) (73)
- The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat. (2018) (72)
- High Rates of Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection in People Who Inject Drugs: A Prospective Cohort Study (2013) (72)
- Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. (2016) (69)
- HCV reinfection incidence among individuals treated for recent infection (2017) (69)
- Plasma interferon‐gamma‐inducible protein‐10 (IP‐10) levels during acute hepatitis C virus infection (2013) (68)
- Uptake of direct‐acting antiviral treatment for chronic hepatitis C in Australia (2018) (68)
- Recommendations for the management of hepatitis C virus infection among people who inject drugs. (2013) (67)
- The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. (2012) (65)
- Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. (2016) (65)
- Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. (2012) (64)
- Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia. (2015) (63)
- Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. (2019) (63)
- Treatment of acute HCV infection (2011) (61)
- Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. (2013) (60)
- Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia (2011) (60)
- Chronic hepatitis C burden and care cascade in Australia in the era of interferon‐based treatment (2017) (60)
- Impact of hepatitis C virus infection on all‐cause and liver‐related mortality in a large community‐based cohort of inner city residents (2011) (60)
- Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study (2015) (60)
- COVID-19 and the health of people who use drugs: What is and what could be? (2020) (59)
- Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada (2014) (59)
- Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration (2017) (57)
- The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program. (2007) (57)
- Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005‐2014: The HITS‐p study (2017) (56)
- Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study (2014) (56)
- The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. (2017) (54)
- The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis. (2019) (54)
- Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study. (2015) (54)
- Management of acute HCV infection in the era of direct-acting antiviral therapy (2018) (53)
- Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. (2019) (53)
- Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study. (2014) (53)
- Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy. (2017) (53)
- Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. (2017) (51)
- Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. (2018) (51)
- Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study (2018) (51)
- The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis (2015) (50)
- Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study (2016) (49)
- Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs. (2011) (49)
- Case definitions for acute hepatitis C virus infection: a systematic review. (2012) (48)
- Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs. (2015) (48)
- Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data? (2015) (48)
- Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity. (2011) (46)
- HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs (2017) (46)
- Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia (2019) (45)
- Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review. (2012) (45)
- The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination. (2019) (45)
- Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia. (2015) (43)
- Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. (2015) (43)
- Current Approaches to HCV Infection in Current and Former Injection Drug Users (2008) (42)
- Recognizing and preventing death from compensated cirrhosis in the community (2012) (42)
- Declining Incidence of Hepatitis C Virus Infection among People Who Inject Drugs in a Canadian Setting, 1996-2012 (2014) (42)
- Effect of pegylated interferon‐α‐2a treatment on mental health during recent hepatitis C virus infection (2012) (42)
- Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. (2018) (40)
- Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C. (2017) (39)
- Estimating the number of people who inject drugs in Australia (2017) (39)
- Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs? (2015) (38)
- Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C‐SCOPE Study (2019) (38)
- Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014). (2016) (38)
- Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy. (2019) (37)
- Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy. (2019) (37)
- Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. (2010) (36)
- Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study. (2018) (36)
- Understanding facilitators and barriers of direct‐acting antiviral therapy for hepatitis C virus infection in prison (2018) (36)
- Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage Study. (2020) (34)
- Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment. (2015) (34)
- Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies (2018) (33)
- Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. (2019) (33)
- Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. (2017) (32)
- Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada. (2015) (31)
- Sequencing of hepatitis C virus for detection of resistance to direct‐acting antiviral therapy: A systematic review (2017) (31)
- Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada. (2019) (31)
- Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre‐ and post‐universal access to direct‐acting antiviral treatment in Australia: The LiveRLife study (2019) (31)
- Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study. (2016) (30)
- Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection (2012) (30)
- Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. (2015) (30)
- Depression, post-traumatic stress disorder, suicidality and self-harm among people who inject drugs: A systematic review and meta-analysis. (2019) (30)
- Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists-The practitioner experience. (2019) (30)
- Naturally Occurring Dominant Drug Resistance Mutations Occur Infrequently in the Setting of Recently Acquired Hepatitis C (2015) (30)
- Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. (2019) (29)
- Global elimination of hepatitis C virus by 2030: why not? (2020) (29)
- Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. (2017) (29)
- Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. (2019) (29)
- Sequencing of the Hepatitis C Virus: A Systematic Review (2013) (29)
- An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study. (2019) (29)
- Dynamics of HCV RNA levels during acute hepatitis C virus infection (2014) (27)
- Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. (2013) (27)
- A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs (2015) (26)
- Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS study (2015) (26)
- A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs-Do Gender-Based Differences Vary by Country-Level Indicators? (2019) (25)
- Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations. (2008) (25)
- Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study. (2021) (25)
- Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: A systematic review and meta-analysis. (2020) (25)
- Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study (2017) (24)
- A molecular phylogenetics-based approach for identifying recent hepatitis C virus transmission events. (2015) (24)
- Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. (2018) (23)
- A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies (2017) (23)
- Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia. (2013) (23)
- Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection (2018) (23)
- Hepatitis C virus testing, liver disease assessment and direct‐acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study (2019) (22)
- HCV reinfection studies and the door to vaccine development. (2009) (21)
- Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. (2022) (20)
- SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy (2017) (20)
- Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada. (2016) (20)
- High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. (2020) (19)
- Differentiation of acute from chronic hepatitis C virus infection by nonstructural 5B deep sequencing: A population‐level tool for incidence estimation (2015) (19)
- Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. (2018) (18)
- Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study (2018) (18)
- Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study (2017) (18)
- Delivery of treatment for hepatitis C virus infection in the primary care setting (2014) (18)
- A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective. (2005) (18)
- Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe (2017) (17)
- Phylogenetic analysis of full‐length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study (2017) (17)
- Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta‐analysis (2021) (17)
- Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model (2020) (17)
- Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international study. (2020) (17)
- Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012 (2018) (17)
- The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study. (2015) (17)
- Time to detection of hepatitis C virus infection with the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a more rapid time to diagnosis. (2020) (16)
- Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada. (2019) (16)
- The Second Canadian Symposium on hepatitis C virus: a call to action. (2013) (16)
- Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs. (2019) (16)
- Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials (2019) (16)
- Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study (2015) (16)
- Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples. (2018) (16)
- Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. (2021) (15)
- Reinfection following successful direct-acting antiviral therapy for hepatitis C infection among people who inject drugs. (2020) (15)
- Frequency of injecting among people who inject drugs: A systematic review and meta-analysis. (2019) (15)
- Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort (2016) (15)
- Perceptions and self-reported competency related to testing, management and treatment of hepatitis C virus infection among physicians prescribing opioid agonist treatment: The C-SCOPE study. (2019) (15)
- Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. (2016) (15)
- The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative (2018) (15)
- Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection (2013) (14)
- Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data (2015) (14)
- Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing. (2019) (14)
- Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. (2017) (14)
- Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada. (2013) (14)
- Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence. (2020) (14)
- Genetics of spontaneous clearance of hepatitis C virus infection: A complex topic with much to learn (2014) (14)
- No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression (2017) (14)
- Deep sequencing increases hepatitis C virus phylogenetic cluster detection compared to Sanger sequencing. (2016) (14)
- Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection (2016) (14)
- Short‐Duration Pan‐Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection (2020) (14)
- Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment (2017) (13)
- Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection (2010) (13)
- Analysis of resistance‐associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents (2017) (13)
- Methadone Dosing Strategies in HIV-Infected Injection Drug Users Enrolled in a Directly Observed Therapy Program (2007) (13)
- Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort (2015) (13)
- Performance evaluation of the Hologic Aptima HCV Quant Dx assay for detection of HCV RNA from dried blood spots. (2019) (12)
- 578 Uptake of hepatitis C virus (HCV) treatment among injection drug users (IDUS) in Vancouver, Canada (2006) (12)
- Treatment of HCV in persons who inject drugs: Treatment as prevention (2017) (12)
- Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis. (2019) (12)
- Associations between housing stability and injecting frequency fluctuations: findings from a cohort of people who inject drugs in Montréal, Canada. (2019) (12)
- Lower life expectancy among people with an HCV notification: a population‐based linkage study (2014) (11)
- Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. (2017) (11)
- HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection. (2016) (11)
- Modelling the potential prevention benefits of a treat‐all hepatitis C treatment strategy at global, regional and country levels: A modelling study (2019) (11)
- Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic. (2020) (11)
- Moving the agenda forward: the prevention and management of hepatitis C virus infection among people who inject drugs. (2013) (11)
- Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis (2019) (10)
- Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis. (2020) (10)
- Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. (2021) (10)
- Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000‐2014) (2017) (10)
- Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: a 15-year observational cohort study. (2015) (10)
- Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. (2021) (10)
- The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments (2017) (9)
- Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications (2021) (9)
- C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT) (2016) (9)
- 60 DIFFERENCES IN EARLY VIROLOGICAL DECLINE IN INDIVIDUALS TREATED WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV SUGGEST A POTENTIAL BENEFIT FOR THE USE OF RIBAVIRIN (2010) (9)
- The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males. (2016) (9)
- Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia. (2017) (9)
- 'I didn't want to let it go too far.' The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study. (2017) (9)
- Primary drug resistance in antiretroviral-naïve injection drug users. (2009) (9)
- The role of re-infection in determining rates of spontaneous clearance after hepatitis C exposure. (2008) (9)
- Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study (2019) (9)
- Competing global statistics on prevalence of injecting drug use: why does it matter and what can be done? (2018) (9)
- Genomic variability of within‐host hepatitis C variants in acute infection (2019) (8)
- Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study. (2014) (8)
- "That was quick, simple, and easy": Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison. (2021) (8)
- Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection (2016) (8)
- A global systematic review of hepatitis C elimination efforts through micro-elimination. (2022) (8)
- Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting. (2020) (8)
- Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system. (2021) (8)
- Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. (2021) (8)
- Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection. (2019) (8)
- The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era. (2014) (8)
- Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: a retrospective cohort study. (2020) (8)
- Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study (2020) (8)
- Prescribing of direct‐acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program (2021) (8)
- HCV Specific IL-21 Producing T Cells but Not IL-17A Producing T Cells Are Associated with HCV Viral Control in HIV/HCV Coinfection (2016) (7)
- Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030. (2017) (7)
- Opportunities to enhance linkage to hepatitis C care among hospitalised people with recent drug dependence in New South Wales, Australia: A population-based linkage study. (2021) (7)
- Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels? (2014) (7)
- Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta‐analysis (2020) (7)
- HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype (2018) (6)
- SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression (2019) (6)
- Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP‐C Treatment as Prevention Study in Prisons (2021) (6)
- A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms (2019) (6)
- A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections. (2019) (6)
- The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges? (2018) (6)
- HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection (2016) (6)
- Reinfection with hepatitis C virus following sustained virological response in injection drug users: HCV reinfection following SVR in IDUs (2009) (6)
- Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan (2016) (6)
- On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome during Therapy with Ledipasvir-Sofosbuvi with or without Ribavirin in the Phase 3 ION-1 Study (2016) (6)
- The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C (2016) (6)
- Hepatitis C: Enhancing treatment for hepatitis C among drug users (2011) (6)
- Clinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy (2007) (5)
- Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies (2016) (5)
- O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study (2017) (5)
- An expanding role for primary care providers in the treatment of hepatitis C virus infection in the community (2011) (5)
- Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies (2016) (5)
- THU-157-Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection (2019) (5)
- Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials (2018) (5)
- Addressing reimbursement disparities for direct‐acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all (2016) (5)
- A latent class approach to identify multi‐risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015 (2019) (5)
- Willingness of people who inject drugs to participate in a randomised controlled trial involving financial incentives to initiate hepatitis C treatment. (2022) (4)
- Concordance between self-reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia. (2021) (4)
- Hepatitis C Virus (HCV) Reinfection and Injection Risk Behavior Following Elbasvir/Grazoprevir (EBR/GZR) Treatment in Patients on Opioid Agonist Therapy (OAT): Costar Three-Year Follow-Up Study (2017) (4)
- Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study. (2022) (4)
- Short and sporadic injecting cessation episodes as predictors of incident hepatitis C virus infection: findings from a cohort study of people who inject drugs in Montréal, Canada. (2019) (4)
- Hepatitis C: A Canadian perspective. (2018) (4)
- Hepatitis C Virus Treatment and Persons Who Inject Drugs (2016) (4)
- Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: Findings from a cross-sectional study in three Australian cities. (2020) (4)
- Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation. (2020) (3)
- The contribution of injecting drug use as a risk factor for Hepatitis C virus transmission globally, regionally, and at country level: a modelling study (2019) (3)
- Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review. (2020) (3)
- 1063 FACTORS ASSOCIATED WITH SPONTANEOUS CLEARANCE DURING ACUTE HEPATITIS C VIRUS INFECTION (2010) (3)
- Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia (2022) (3)
- 6th Canadian Symposium on Hepatitis C Virus: Delivering a cure for hepatitis C infection-What are the remaining gaps? (2018) (3)
- 1157 EARLY HCVRNA DYNAMICS AND FACTORS ASSOCIATED WITH HIGH EARLY HCVRNA LEVEL DURING ACUTE HCV INFECTION (2013) (3)
- Australia on track to achieve WHO elimination targets following rapid initial DAA treatment uptake (2018) (3)
- Injecting frequency trajectories and hepatitis C virus acquisition: Findings from a cohort of people who inject drugs in Montréal, Canada. (2021) (3)
- Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. (2021) (3)
- Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study. (2021) (3)
- Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach (2018) (3)
- Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types. (2015) (3)
- Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the SToP-C study (2017) (3)
- Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel. (2021) (3)
- SHARED: An International Collaboration to Unravel Hepatitis C Resistance (2021) (3)
- 894 FEMALE SEX AND VARIATIONS IN IL28B ARE INDEPENDENTLY ASSOCIATED WITH SPONTANEOUS CLEARANCE OF ACUTE HCV INFECTION (2012) (3)
- Global patterns of opioid use and dependence: Population harms, interventions, and future action (2019) (3)
- Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada. (2021) (3)
- Treatment of hepatitis C virus infection among people who inject drugs: uptake and outcome (2016) (2)
- Declining HCV incidence following rapid HCV treatment scale-up in a prison network in Australia: Evidence of treatment as prevention from the SToP-C study (2020) (2)
- Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study. (2023) (2)
- Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial (2020) (2)
- Evaluation of the Aptima HCV Quant Dx Assay for HCV RNA detection from finger-stick capillary dried blood spot and venepuncture-collected samples. (2020) (2)
- Hepatitis C Virus Core Antigen: A Simplified Treatment Monitoring Tool, including for Post-Treatment Relapse (2016) (2)
- Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection. (2021) (2)
- 1328 IL28B GENOTYPE HAS VARIABLE INFLUENCE ON EARLY VIRAL KINETICS, BUT NO INFLUENCE ON SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION (2011) (2)
- Harm reduction strategies to prevent new infections and reinfections among people who inject drugs: how effective are they? (2020) (2)
- Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. (2023) (2)
- Diagnostic accuracy of assays using point-of-care testing or dried blood spot samples for the determination of HCV RNA: a systematic review. (2022) (2)
- Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review. (2023) (2)
- New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an Addiction series. (2017) (2)
- COHORT PROFILE Cohort Profile : The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts ( InC 3 ) Study (2014) (2)
- CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection (2010) (2)
- The 7th Canadian Symposium on Hepatitis C Virus: "Toward Elimination of HCV: How to Get There". (2018) (2)
- Direct-acting antivirals for acute HCV: how short can we go? (2017) (2)
- Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study (2018) (2)
- PS-070-Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage study (2019) (2)
- "You need a designated officer" - Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting. (2022) (1)
- Hepatitis C virus‐specific immune responses following direct‐acting antivirals administered during recent hepatitis C virus infection (2022) (1)
- Creating an environment for equitable access to direct‐acting antiviral therapy for people who inject drugs with hepatitis C (2020) (1)
- Time for a systematic approach to the treatment of hepatitis C virus infection in injection drug users (2006) (1)
- Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals (2022) (1)
- A summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses. (2014) (1)
- Incidence of HCV Reinfection among Treated Individuals with Recently Acquired Infection (2016) (1)
- Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative (2016) (1)
- O9 Progress towards elimination: rapid uptake of HCV treatment among people who inject drugs following broad access to DAA therapies (2017) (1)
- 785 CONTINUED LOW UPTAKE OF TREATMENT FOR HCV IN A LARGE COMMUNITY-BASED COHORT OF INNER CITY RESIDENTS (2013) (1)
- 276 WEEK 4 HCV RNA IS THE OPTIMAL PREDICTOR OF SVR IN BOTH HIV POSITIVE AND NEGATIVE SUBJECTS WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV (2010) (1)
- 453 SIGNATURE RESISTANCE MUTATIONS TO DIRECTLY ACTING ANTIVIRAL AGENTS OCCUR AT LOW PREVALENCE IN TREATMENT NAIVE SUBJECTS WITH RECENTLY ACQUIRED HEPATITIS C INFECTION (2011) (1)
- Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study (2020) (1)
- Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study (2022) (1)
- Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian ‘surveillance and treatment of prisoners with hepatitis C’ project (SToP-C) (2021) (1)
- Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis. (2022) (1)
- Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study. (2022) (1)
- Hepatitis C virus cascade of care among people who inject drugs: a cross-sectional study of characteristics associated with HCV testing and treatment in Australia (2019) (1)
- P762 TEMPORAL CHANGES IN HEPATITIS C VIRUS GENOTYPE 3A DISTRIBUTION AMONG PEOPLE WHO INJECT DRUGS IN VANCOUVER, CANADA (2014) (1)
- Comparing Individual and Population Prevention Benefits of Early Direct-Acting Antiviral Treatment for HCV (2016) (1)
- Who should be prioritized for HCV antiviral treatment? A cost-effectiveness analysis including individual and population prevention benefits (2014) (1)
- The contribution of injecting drug use to Hepatitis C virus transmission globally, regionally, and at country level: a modelling study (2018) (1)
- 889 PLASMA IP10 LEVEL PREDICTS SPONTANEOUS CLEARANCE IN ACUTE HCV INFECTION (2012) (1)
- The 8th Canadian Symposium on Hepatitis C virus: "Improving diagnosis and linkage to care". (2020) (1)
- Evaluation of the Xpert fingerstick HCV viral load assay (2018) (1)
- Cure and Control: What Will It Take to Eliminate HCV? (2019) (1)
- Hepatitis C lipoviral particle levels are associated with spontaneous clearance of acute infection (2014) (1)
- 1178 MOLECULAR EPIDEMIOLOGY OF HEPATITIS C IN A SOCIAL NETWORK OF YOUNG PEOPLE WHO INJECT DRUGS (2011) (1)
- P079: Hepatitis B and C among people who inject drugs in Germany: High HCV prevalence, low HBV immunization rates, and urgent need for prevention (2015) (1)
- 'Not just one box that you tick off' - Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective. (2022) (1)
- P080: Characterizing hepatitis C virus transmission dynamics using molecular phylogenetic‐based methods (2015) (1)
- 402 IMPACT OF HEPATITIS C VIRUS INFECTION ON LIVER- RELATED MORTALITY IN A LARGE COMMUNITY-BASED COHORT OF INNER CITY RESIDENTS (2009) (1)
- 965 TRENDS IN MORTALITY AFTER DIAGNOSIS OF HEPATITIS C INFECTION – AN INTERNATIONAL COMPARISON (2013) (1)
- A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study (2022) (1)
- A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia. (2023) (1)
- Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study. (2022) (1)
- 461 SPONTANEOUS CLEARANCE OF ACUTE HCV INFECTION IS ASSOCIATED WITH FEMALE SEX, IL28B GENOTYPE AND HCV GENOTYPE 1 INFECTION (2013) (1)
- Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. (2015) (1)
- Hepatitis C virus core antigen and dried blood spots as simplified hepatitis C virus diagnostic tools (2017) (1)
- Reducing barriers to the hepatitis C care cascade in prison via point-of-care RNA testing: A qualitative exploration of men in prison using an integrated framework. (2023) (1)
- Hepatitis C virus infection in injection drug users (2007) (1)
- THU-403-The consensus hepatitis C cascade of care: Methodology and initial findings from three countries (2019) (1)
- Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection. (2022) (1)
- A165 SHORT INJECTION CESSATION EPISODES AS OPPORTUNITIES FOR HEPATITIS C PREVENTION (2018) (0)
- Prison‐based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study (2022) (0)
- Associations between the prevalence of chronic hepatitis B among people who inject drugs and country-level characteristics: An ecological analysis. (2023) (0)
- Improved survival following Hepatitis C-related hepatocellular carcinoma diagnosis in the direct-acting antiviral therapy era in New South Wales, Australia (2019) (0)
- Factors associated with hepatitis C virus RNA levels in early acute and early chronic infection: the InC3 study (2014) (0)
- Patient-reported outcomes among people receiving opioid agonist therapy and treatment for hepatitis C virus infection: results from CO-STAR (2020) (0)
- Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison (2017) (0)
- that may be Markov-chain Monte Carlo analysis of observational study data. (2014) (0)
- 1159 SEQUENCING THE HEPATITIS C VIRUS: A SYSTEMATIC REVIEW (2013) (0)
- O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study (2017) (0)
- Abstracts of the Australasian Viral Hepatitis Elimination Conference: poster presentations (2017) (0)
- The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international comparison study (2017) (0)
- P081: Birth cohort and risk factors in Hepatitis C patients recorded at the Sentinel Units Network in Argentina 2007–2014 (2015) (0)
- Comparing the prevention gains of different treatment strategies at the global, regional, and country level: a modelling study (2018) (0)
- Evaluation of a hepatitis C virus core antigen assay in dried-blood spots: a cohort study (2018) (0)
- Hepatitis C in South Australia And Northern Territory: A Population-Based Linkage Study (2020) (0)
- Hepatitis C virus network dynamics among people who inject drugs in Vancouver, Canada (2014) (0)
- A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms (2019) (0)
- HCV infection: findings from the InC3 Collaborative (2016) (0)
- SAT-232-Reinfection following successful HCV DAA therapy among people with recent injecting drug use (2019) (0)
- Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy (2022) (0)
- Interferon alfa (1994) (0)
- 843Hepatitis C in South Australia and Northern Territory: a population-based linkage study (2021) (0)
- P0883 : Treatment for hepatitis C virus infection among people who inject drugs in the opioid substitution setting: The ethos study (2015) (0)
- Does Alcohol Dependency Explain Differences in Rates of Decompensated Cirrhosis among People with a Hepatitis C Notification? An International Comparison (2016) (0)
- Systematic approach to the treatment of HCV infection in injection drug users: where are we now? (2009) (0)
- People engaged in opioid agonist treatment as a counterpublic during the COVID‐19 pandemic in Australia: A qualitative study (2022) (0)
- Target Population : patients with acute hepatitis C virus infection Setting : (2015) (0)
- Title: Reinfection with hepatitis C virus following sustained virological response in injection drug users Running title: HCV reinfection following SVR in IDUs (2016) (0)
- Patient reported outcomes during and following HCV direct-acting antiviral treatment among people who inject drugs. (2023) (0)
- 429 IMPACT OF TREATMENT ON INJECTING DRUG USE BEHAVIORS DURING RECENT HCV INFECTION: THE ATAHC STUDY (2011) (0)
- “You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic (2023) (0)
- P214 Molecular epidemiology of newly acquired hepatitis C virus (HCV) infections in British Columbia (2009) (0)
- A161 ONGOING INCIDENT HEPATITIC C VIRUS INFECTION AMONG PEOPLE WITH A HISTORY OF INJECTING DRUG USE IN AN AUSTRALIAN PRISON SETTING (2018) (0)
- Reduced Hepatitis C Incidence Associated with Rapid Treatment Scale-Up in Australian Prisons: Treatment-as-Prevention in the SToP-C Study (2020) (0)
- Global elimination of hepatitis C virus by 2030: why not? (2020) (0)
- A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT) (2018) (0)
- 1152 IP-10 IS ASSOCIATED WITH EARLY VIRAL KINETICS, BUT NOT SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION (2011) (0)
- 811 RESPONSE TO TREATMENT FOLLOWING RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION (2013) (0)
- O6 Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the StoP-C study (2017) (0)
- Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance (2017) (0)
- Field evaluation of Xpert ® HCV Viral Load point-of-care test for detection of hepatitis C virus infection by venipuncture-collected and finger-stick capillary whole-blood samples (2017) (0)
- Physician Perceptions of and Competency in Hepatitis C Testing, Management, and Treatment Survey Questionnaire (2020) (0)
- A239 QUALITATIVE EVALUATION OF THE DECISIONS AND EXPERIENCES OF PEOPLE WHO INJECT DRUGS WHO RECEIVED A LIVER DISEASE ASSESSMENT AS PART OF A LIVER HEALTH PROMOTION CAMPAIGN: THE LIVERLIFE STUDY (2018) (0)
- Treatment of recent hepatitis C virus infection in a predominantly injection drug user cohort: the ATAHC Study (2009) (0)
- Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis (2023) (0)
- Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs. (2015) (0)
- P232 MOLECULAR PHYLOGENETICS OF HEPATITIS C VIRUS (HCV) AS A TOOL TO UNDERSTAND THE HCV EPIDEMIC IN BRITISH COLUMBIA (BC), CANADA (2014) (0)
- One-year injecting frequency trajectories as predictors of hepatitis C acquisition: findings from an observational cohort study of people who inject drugs in Montréal, Canada (2018) (0)
- Decentralised point-of-care testing for acute, chronic and infectious disease – benefits and challenges (2023) (0)
- Diagnosis of hepatitis c virus infection after entry to opioid substitution therapy (2015) (0)
- Hepatitis C virus core antigen: A simplified treatment monitoring tool among those with recent Hepatitis C virus infection, including for post-treatment relapse (2016) (0)
- Perceptions of extended-release buprenorphine injections for opioid dependence prior to availability in Australia: a cross-sectional survey of people who use opioids regularly (2019) (0)
- Reply: (2007) (0)
- A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study. (2023) (0)
- Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection (2016) (0)
- 'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue. (2023) (0)
- Hepatitis C Virus Transmission Dynamics in a Global Cohort of Men Who Have Sex with Men with Recently Acquired Infection (2022) (0)
- A framework for hepatitis C virus treatment as prevention in the prison setting: the SToP-C implementation toolkit (2017) (0)
- SOF/VEL for 12 Weeks Is Well Tolerated and Results in High SVR12 Rates in People Receiving Opioid Substitution Therapy (2016) (0)
- Incidence and risk factors of hepatitis C liver morbidity and mortality in the era of direct-acting antiviral therapies: a population-based linkage study (2022) (0)
- Protease and Polymerase Inhibitors for the Treatment of Hepatitis C Virus Infection (2010) (0)
- Substitution of tenofovir for nucleoside analogues in virologically controlled HIV-infected patients co-infected with hepatitis C virus: TEN-SWITCH (2008) (0)
- Cover Image (2018) (0)
- Agreement between self-reported illicit drug use and biological samples: A systematic review and meta-analysis. (2023) (0)
- Stable Incidence of Hepatitis C Virus Infection among People with a History of Injecting Drug Use in an Australian Prison Setting, 2005–2014: The Hits-P Study (2016) (0)
- Hepatitis C virus exposure, infection and associated risk behaviours in two maximum-security prisons in New South Wales, Australia (2016) (0)
- Injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting, 2005–2014: the HITS-p study (2017) (0)
- Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study. (2022) (0)
- P0848 : Efficacy of response-guided pegylated interferon and ribavirin therapy for people who inject drugs with HCV genotype 2/3 infection: The activate study (2015) (0)
- Hepatitis C care cascade before and during the direct‐acting antiviral eras in New South Wales, Australia: A population‐based linkage study (2022) (0)
- Evaluation of Simplified HCV Diagnostics in HIV/HCV Co-Infected Patients in Myanmar (2023) (0)
This paper list is powered by the following services:
Other Resources About Jason Grebely
What Schools Are Affiliated With Jason Grebely?
Jason Grebely is affiliated with the following schools:
